Advertisement

Safety and Utility of Liver Biopsy During Bariatric Surgery in the New Zealand Setting

  • Hannah CollinsEmail author
  • Grant Beban
  • John Windsor
  • Rishi Ram
  • David Orr
  • Nicholas Evennett
  • Benjamin Loveday
Original Contribution

Abstract

Background

Asymptomatic liver disease is common in bariatric patients and can be diagnosed with intraoperative biopsy. This study aimed to establish the risk-benefit profile of routine liver biopsy, prevalence of clinically significant liver disease, relationship between liver pathology and body mass index, and compare outcomes between ethnic groups.

Methods

This retrospective cohort study included all patients who had index bariatric surgery at Auckland City Hospital between 2009 and 2016. Diagnosis of liver disease was based on intraoperative biopsy histology. Outcomes included safety (biopsy-related complication) and utility (liver pathology meeting criteria for referral). Liver pathology and referral rates were compared between ethnic groups.

Results

Of 335 bariatric surgery patients, 234 (70%) underwent intraoperative liver biopsy. There were no biopsy-related complications. Histological findings were as follows: normal 25/234 (11%), non-alcoholic fatty liver disease (NAFLD) 207/234 (88%), and other pathological findings in 35/234 (15%). Histological finding meeting referral criteria was present in 22/234 (9%). Of these, 12/22 (55%) were referred. Number needed to biopsy to identify histology meeting referral criteria: n = 11. Māori had a similar NAFLD rate to non-Māori [51/56 versus 156/178, p = 0.48]. Pasifika patients had a higher rate than non-Pasifika [39/40 versus 168/194, p = 0.049]. Māori and Pasifika patients had similar referral rates to non-Māori and non-Pasifika [2/3 versus 5/9, p = 0.73; 2/2 versus 5/10, p = 0.19].

Conclusions

Intraoperative liver biopsy during bariatric surgery is safe and identified liver disease in 89%, with 9% meeting referral criteria. Pasifika patients have a higher rate of NAFLD than non-Pasifika.

Keywords

Bariatric surgery Liver biopsy Non-alcoholic fatty liver disease Hepatology 

Notes

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflict of interest.

Ethical Statement

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

For this type of study, formal consent is not required.

Ethics approval from Central Health and Disability Ethics Committee, Ministry of Health, Wellington, New Zealand. Ethics ref. 17/CEN/127.

Consent Statement

This was a retrospective study where no identifying data was collected. All data was collected in a de-identified database by a single investigator. Informed consent was not required.

References

  1. 1.
    Machado M, Marques-Vidal P, Cortez-Pinto H. Hepatic histology in obese patients undergoing bariatric surgery. J Hepatol. 2006;45(4):600–6.CrossRefGoogle Scholar
  2. 2.
    Mofrad P, Contos MJ, Haque M, et al. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology. 2003;37(6):1286–92.CrossRefGoogle Scholar
  3. 3.
    Sorrentino P, Tarantino G, Conca P, et al. Silent non-alcoholic fatty liver disease - a clinical-histological study. J Hepatol. 2004;41(5):751–7.CrossRefGoogle Scholar
  4. 4.
    Castéra L, Foucher J, Bernard PH, et al. Pitfalls of liver stiffness measurement: a 5-year prospective study of 13,369 examinations. Hepatology. 2010;51(3):828–35.PubMedGoogle Scholar
  5. 5.
    Myers RP, Pomier-Layrargues G, Kirsch R, et al. Discordance in fibrosis staging between liver biopsy and transient elastography using the FibroScan XL probe. J Hepatol. 2012;56(3):564–70.CrossRefGoogle Scholar
  6. 6.
    Dulai PS, Sirlin CB, Loomba R. MRI and MRE for non-invasive quantitative assessment of hepatic steatosis and fibrosis in NAFLD and NASH: clinical trials to clinical practice. J Hepatol. 2016;65(5):1006–16.CrossRefGoogle Scholar
  7. 7.
    Teixeira AR, Bellodi-Privato M, Carvalheira JB, et al. The incapacity of the surgeon to identify NASH in bariatric surgery makes biopsy mandatory. Obes Surg. 2009;19(12):1678–84.CrossRefGoogle Scholar
  8. 8.
    Dolce CJ, Russo M, Keller JE, et al. Does liver appearance predict histopathologic findings: prospective analysis of routine liver biopsies during bariatric surgery. Surg Obes Relat Dis. 2009;5(3):323–8.CrossRefGoogle Scholar
  9. 9.
    Leoni S, Tovoli F, Napoli L, et al. Current guidelines for the management of non-alcoholic fatty liver disease: a systematic review with comparative analysis. World J Gastroenterol. 2018;24(30):3361–73.CrossRefGoogle Scholar
  10. 10.
    Praveenraj P, Gomes RM, Kumar S. Prevalence and predictors of non-alcoholic fatty liver disease in morbidly obese South Indian patients undergoing bariatric surgery. Obes Surg. 2015;5(11):2078–87.CrossRefGoogle Scholar
  11. 11.
    Petrick A, Benotti P, Wood GC, et al. Utility of ultrasound, trans-aminases, and visual inspection to assess nonalcoholic fatty liver disease in bariatric surgery patients. Obes Surg. 2015;25(12):2368–75.CrossRefGoogle Scholar
  12. 12.
    Froehlich F, Lamy O, Fried M, et al. Practice and complications of liver biopsy. Dig Dis Sci. 1993;38(8):1480–4.CrossRefGoogle Scholar
  13. 13.
    Janes CH, Lindor KD. Outcome of patients hospitalized for complications after outpatient liver biopsy. Ann Intern Med. 1993;118(2):96–8.CrossRefGoogle Scholar
  14. 14.
    Thampanitchawong P, Piratvisuth T. Liver biopsy: complications and risk factors. World J Gastroenterol. 1999;5(4):301–4.CrossRefGoogle Scholar
  15. 15.
    Population of Auckland AHB. Ministry of Health; [updated 2019 February 25; cited 2019 June 10]. Available from: https://www.health.govt.nz/new-zealand-health-system/my-dhb/auckland-dhb/population-auckland-dhb.
  16. 16.
    Obesity statistics. Ministry of health; [updated 2018 November 15; cited 2019 June 10]. Available from: https://www.health.govt.nz/nz-health-statistics/health-statistics-and-data-sets/obesity-statistics.
  17. 17.
    Pasifika People in NZ. Ministry for Pasifika Peoples. [Cited 2019 June 10]. Available from: https://www.mpp.govt.nz/Pasifika-people-in-nz.
  18. 18.
    Devereaux PJ, Mrkobrada M, Sessler DI, et al. Aspirin in patients undergoing noncardiac surgery. N Engl J Med. 2014;370(16):1494–503.CrossRefGoogle Scholar
  19. 19.
    Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240(2):205–13.CrossRefGoogle Scholar
  20. 20.
    Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41(6):1313–21.CrossRefGoogle Scholar
  21. 21.
    McCormack L, Yeh L-C, Braybrook B, et al. Tupu Ola Moui. Pasifika health chart book 2012. Wellington: Ministry of Health; 2012. [cited 2019 25 Feb]. Available from: https://www.health.govt.nz/publication/tupu-ola-moui-Pasifika-health-chart-book-2012 Google Scholar
  22. 22.
    Ministry of Health. Ethnicity data protocols. Wellington: Ministry of Health; 2017. [cited 2019 26 Feb]. Available from: https://www.health.govt.nz/publication/hiso-100012017-ethnicity-data-protocols Google Scholar
  23. 23.
    Hsiang J. Chronic liver diseases: with a focus on hepatitis B, type 2 diabetes, and statins [PhD thesis]. [Auckland]: University of Auckland; 2016. 161 p.Google Scholar
  24. 24.
    Agresti A. An introduction to categorical data analysis. 2nd ed. New Jersey: John Wiley & Sons, Inc; 2007.CrossRefGoogle Scholar
  25. 25.
    Barbois S, Arvieux C, Leroy V, et al. Benefit–risk of intraoperative liver biopsy during bariatric surgery: review and perspectives. Surg Obes Relat Dis. 2017;13(10):1780–6.CrossRefGoogle Scholar
  26. 26.
    Helling TS, Helzberg JH, Nachnani JS, et al. Predictors of nonalcoholic steatohepatitis in patients undergoing bariatric surgery: when is liver biopsy indicated? Surg Obes Relat Dis. 2008;4(5):612–7.CrossRefGoogle Scholar
  27. 27.
    Kleiner DE, Berk PD, Hsu JY, et al. Hepatic pathology among patients without known liver disease undergoing bariatric surgery: observations and a perspective from the Longitudinal Assessment of Bariatric Surgery (LABS) Study. Semin Liver Dis. 2014;34(1):98–107.CrossRefGoogle Scholar
  28. 28.
    Simo KA, McKillop IH, McMillan MT, et al. Does a calculated “NAFLD fibrosis score” reliably negate the need for liver biopsy in patients undergoing bariatric surgery? Obes Surg. 2013;24(1):15–21.CrossRefGoogle Scholar
  29. 29.
    Mahawar KK, Parmar C, Graham Y, et al. Routine liver biopsy during bariatric surgery: an analysis of evidence base. Obes Sur. 2016;26(1):177–81.CrossRefGoogle Scholar
  30. 30.
    Mattar SG, Velcu LM, Rabinovitz M, et al. Surgically-induced weight loss significantly improves nonalcoholic fatty liver disease and the metabolic syndrome. Ann Surg. 2005;242(4):610–7.PubMedPubMedCentralGoogle Scholar
  31. 31.
    Mummadi RR, Kasturi KS, Chennareddygari S, et al. Effect of bariatric surgery on nonalcoholic fatty liver disease: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2008;6(12):1396–402.CrossRefGoogle Scholar
  32. 32.
    Brenner DA. Reversibility of liver fibrosis. Gastroenterol Hepatol. 2013;9(11):737–9.Google Scholar
  33. 33.
    Lee Y, Doumouras AG, Yu J, et al. Complete resolution of nonalcoholic fatty liver disease after bariatric surgery: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2019;17(6):1040–60.CrossRefGoogle Scholar
  34. 34.
    Mahawar KK, Parmar C, Graham Y, et al. Monitoring of liver function tests after Roux-en-Y gastric bypass: an examination of evidence base. Obes Surg. 2016;26(10):2516–22.CrossRefGoogle Scholar
  35. 35.
    Coppell KJ, Miller JC, Gray AR, et al. Obesity and the extent of liver damage among adult New Zealanders: findings from a national survey. Obes Sci Pract. 2015;1(2):67–77.CrossRefGoogle Scholar
  36. 36.
    Health Quality & Safety Commission New Zealand. Atlas of healthcare variation. [cited 2019 Jan 17]. Available from: https://www.hqsc.govt.nz/our-programmes/health-quality-evaluation/projects/atlas-of-healthcare-variation/diabetes.
  37. 37.
    Crantock LR, Dillon JF, Hayes PC. Diagnostic laparoscopy and liver disease: experience of 200 cases. Aust NZ J Med. 1994;24(3):258–62.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Auckland City HospitalAucklandNew Zealand
  2. 2.University of AucklandAucklandNew Zealand
  3. 3.University of MelbourneMelbourneAustralia

Personalised recommendations